STTK · Shattuck Labs

The thesis

Shattuck Labs has no patient efficacy data for its lead drug SL-325 until the first half of 2028, so the shares trade on the pipeline story and on trial-start milestones. The third-quarter report on 5 November 2026 confirmed both Phase 2 programmes are moving and that cash is guided to last into 2029; the shares still closed at $4.99 on 9 November 2026.

SL-325 blocks death receptor 3 (DR3), the receptor for the inflammatory protein TL1A. The 8 June 2026 Phase 1 release reported complete receptor occupancy at doses of 0.1 mg/kg and above in 72 healthy volunteers. No Crohn's disease, ulcerative colitis or hidradenitis suppurativa (HS) patient has appeared in a reported efficacy dataset.

The Q3 release (SEC Form 8-K, 5 November 2026) added three facts. The Phase 2b RECEPTIVE-CD1 trial in Crohn's disease has started: about 232 patients, three dose levels against placebo, endoscopic response at 12 weeks as the primary endpoint, data in the first half of 2028. The investigational new drug (IND) application for RECEPTIVE-HS1 in HS was submitted in October 2026, with trial initiation expected in the fourth quarter. Cash was $196.3 million at 30 September 2026.

The shares closed at $4.99 on 9 November 2026, one cent under $5.00. The business conditions in that note have not broken: the IND was filed and the Crohn's trial began. The shares are falling into a two-year gap before any efficacy data.

The story is well known: the pipeline story is well known, four brokerages have initiated since 24 August 2026, and the shares closed at $6.84 on 1 October 2026, $5.77 on 27 October 2026 and $4.99 on 9 November 2026.

Bullish and bearish views on Shattuck Labs, Inc.

The bull case on Shattuck Labs, Inc. (STTK), in brief: human target engagement is measured. The bear case: no patient data exists.

Bull case

• Human target engagement is measured. The 8 June 2026 release reported complete DR3 occupancy at 0.1 mg/kg and above in 72 healthy volunteers. That shows the drug reaches its target in people.
• Both Phase 2 trials are on schedule. RECEPTIVE-CD1 started and the RECEPTIVE-HS1 IND was submitted in October, as guided (Q3 release, 5 November 2026). The company guides data from both in the first half of 2028.
• Cash is guided to 2029. Cash, cash equivalents and short-term investments were $196.3 million at 30 September 2026, and management expects them to fund operations into 2029 (SEC Form 8-K, 5 November 2026).
• Sell-side targets sit far above the price. Raymond James initiated at Strong Buy with an $18 target on 24 August 2026, UBS at Buy with $17 on 12 October 2026 and Evercore at Buy on 21 October 2026 (Benzinga). Investing.com showed an average target of $14.25 from 10 analysts on 21 August 2026.

Bear case

• No patient data exists. The Phase 1 trial enrolled healthy volunteers only and reported anti-drug antibodies in 3.7% of treated participants (8 June 2026). Receptor occupancy does not measure endoscopic response or HiSCR50 response.
• Both readouts sit in 2028. Management guides Phase 2 data in Crohn's disease and HS to the first half of 2028. The only earlier dataset is SL-846 Phase 1, guided to 2027.
• Spending has stepped up. R&D expense was $21.6 million in Q3 2026 versus $7.6 million in Q3 2025, and $11.7 million in Q2 2026 (company releases). The net loss was $25.2 million, or $0.14 per share.
• Cash fell and the share count rose. Cash and short-term investments were $196.3 million at 30 September 2026 against $208.3 million at 30 June 2026. Weighted-average shares were 183.2 million in Q3 2026 versus 72.2 million in Q3 2025, and additional paid-in capital rose from $512.9 million to $679.4 million over nine months (Form 8-K).
• The shares have not followed the targets. The shares are 38.1% under the 52-week high of $8.06 and fell 33.4% over three months to 9 November 2026. Initiations in August and October did not hold the price.

Price setup

The adjusted daily close was $4.99 on 9 November 2026. That is 38.1% under the 52-week high of $8.06, with a 3-month decline of 33.4% and a 14-day Relative Strength Index (RSI) of 34.9. An RSI under 30 marks heavily sold shares; 34.9 is near that zone but not in it.

The shares closed at $6.84 on 1 October 2026 and $5.77 on 27 October 2026, so the decline continued through the Q3 report. No round-number level between $4.99 and $4.50 is tied to a business event.

On crowding, no gap above a rising moving average exists, since the shares are in a downtrend. The observable crowding is on the sell-side: consensus targets of $10 to $18 (Investing.com, 21 August 2026) against a $4.99 close. The share count more than doubled year over year (Form 8-K), a dilution fact rather than a demand fact. The retail-attention and insider-transaction records were not checked for this note.

Catalysts ahead

• 31 December 2026 (Q4 guided): Company-guided start of the Phase 2 RECEPTIVE-HS1 trial of SL-325 in hidradenitis suppurativa; the IND was submitted in October 2026. A first-patient or site-activation announcement shows the second indication is moving on the guided schedule; a slip into 2027 would move the first-half 2028 readout.
• ~2027 (est.): SL-846 (DR3 x IL-23R bispecific) Phase 1 healthy-volunteer trial start and initial data, guided to 2027. The next dataset of any kind; it sets the length of the news gap before the SL-325 Phase 2 readouts.
• H1 2028 (guided): RECEPTIVE-CD1 induction data in Crohn's disease and RECEPTIVE-HS1 HiSCR50 data in hidradenitis suppurativa. The first patient efficacy evidence for SL-325; these results settle the thesis.

What would change the view

A daily close above $6.31, 25% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

Shattuck trades with small and mid-cap clinical-stage biotech, where moves track funding conditions and sentiment toward pre-revenue companies more than company news. The closest read-across is the TL1A class: Merck's tulisokibart and Roche's afimkibart target the ligand rather than the receptor, and a clear success or failure in inflammatory bowel disease would shift the whole mechanism. The shares carry no product revenue, so earnings season in the broader market has little direct effect.